Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 12;13:948190. doi: 10.3389/fimmu.2022.948190

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Golomingi, Kohler, Jenny, Hardy, Dobó, Gál, Pál, Kiss, Lam and Schroeder

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of MASP-1-inhibition in the bleeding model. To investigate the effects of the MASP-1 inhibitor SGMI-1, the signal intensity relative to the first time point was monitored for activated platelets (CD62P) (A) and fibrin (B). A) Both concentrations of SGMI (20.4 μg/ml; n=4 and 40.8ug/ml; n=2) resulted in a reduced increase of the CD62P signal in comparison to the control (n=6). B) Fibrin deposition was reduced in the presence of SGMI-1 (n=3). The area under the curve (C) was measured using GraphPad Prism. (D) SGMI-1 prolonged the bleeding time (n=3). Data are shown as mean with SD, and p-values for differences between groups were determined with ANOVA or t-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001).